Safety and tolerability to long term moxifloxacin treatment in 38 patients with difficult to manage tuberculosis: preliminary data

L. R. Codecasa, M. Ferrarese, V. Penati, C. Lacchini, G. B. Migliori (Milan, Tradate, Italy)

Source: Annual Congress 2004 - Management and resistance in tuberculosis
Session: Management and resistance in tuberculosis
Session type: Poster Discussion
Number: 4426
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. R. Codecasa, M. Ferrarese, V. Penati, C. Lacchini, G. B. Migliori (Milan, Tradate, Italy). Safety and tolerability to long term moxifloxacin treatment in 38 patients with difficult to manage tuberculosis: preliminary data. Eur Respir J 2004; 24: Suppl. 48, 4426

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Evaluation of efficacy and safety of linezolid for the treatment of drug-resistant tuberculosis: case series report of 12 patients
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009


Evaluation of the efficacy and safety of levofloxacin in the treatment of resistant pulmonary tuberculosis; a clinical trial
Source: Eur Respir J 2002; 20: Suppl. 38, 546s
Year: 2002

Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses
Source: Eur Respir J, 50 (1) 1700061; 10.1183/13993003.00061-2017
Year: 2017



Evaluation of the efficacy and safety of moxifloxacin in the treatment of drug-resistant pulmonary tuberculosis; a clinical trial
Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis
Year: 2008



Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis
Source: Eur Respir J 2012; 40: 1430-1442
Year: 2012



Audit of long term azithromycin therapy in clinical practice
Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections
Year: 2010


Clinical benefits and safety of long term treatment with montelukast (M) in patients with mild-to-moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 261s
Year: 2001

Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China
Source: Eur Respir J 2016; 47:1591-1592
Year: 2016


Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China
Source: Eur Respir J 2015; 45: 161-170
Year: 2015



A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis
Source: Eur Respir J 2009; 33: 387-393
Year: 2009



A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen
Source: Eur Respir J 2001; 18: Suppl. 33, 189s
Year: 2001

First data about the efficacy of moxifloxacin in the treatment of pulmonary tuberculosis – a prospective, randomised study versus INH
Source: Annual Congress 2003 - Management of tuberculosis and tubercular infection - old and new considerations
Year: 2003


Long term efficacy and safety of omalizumab in patients with allergic asthma-A real life study
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020


Efficacy, safety and tolerability of 3 day azithromycin versus 10-day amoxillin/clavulanic acid in the treatment of children with pneumonia
Source: Eur Respir J 2003; 22: Suppl. 45, 143s
Year: 2003

Safety, tolerability and efficacy of linezolid for the treatment of M/XDR-TB: A systematic review and meta-analysis
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011


New short regimens for latent tuberculosis treatment: safety first!
Source: Eur Respir J, 52 (6) 1802180; 10.1183/13993003.02180-2018
Year: 2018



Clinical benefits and safety of long term treatment with Montelukast in children with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 525s
Year: 2002

The efficacy, safety and tolerability of the short 12-month MDR-TB regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase
Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now?
Year: 2017



Efficacy and long-term safety of ciclesonide in asthmatic patients as demonstrated in a 52 week long study
Source: Eur Respir J 2002; 20: Suppl. 38, 373s
Year: 2002

Short 12-month regimen with intravenouse linezolid for MDR-TB:  treatment outcomes and first follow up results.
Source: International Congress 2018 – New developments in tuberculosis
Year: 2018